DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Assoc. Prof. Marius Rademaker, Dermatologist, Hamilton, New Zealand, 2004. Updated by A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, January 2016.
Drug hypersensitivity syndrome is a severe, unexpected reaction to a medicine, which affects several organ systems at the same time. It most commonly causes the combination of:
Drug hypersensitivity syndrome is sometimes also called drug reaction with eosinophilia and systemic symptoms (DRESS), and drug-induced hypersensitivity syndrome (DIHS).
The syndrome is classified as a severe cutaneous adverse reaction (SCAR). It may have overlapping features with Stevens–Johnson syndrome / toxic epidermal necrolysis (SJS/TEN) and acute generalised exanthematous pustulosis (AGEP).
Drug hypersensitivity syndrome is relatively rare. It mainly affects adults and is equal in incidence in males and females. Genetic susceptibility and HLA associations have been found for several causative drugs.
The most common drugs to cause this reaction are a number of anti-epilepsy drugs (particularly carbamazepine, phenobarbital and phenytoin), the anti-gout drug, allopurinol, olanzapine, and the sulphonamide group of antibiotics. It has been estimated that at least 1 in every 10,000 patients treated with an anticonvulsant will develop drug hypersensitivity syndrome.
The risk of drug hypersensitivity syndrome in patients on allopurinol depends on the dose of allopurinol. It is greater if the patient has kidney disease and if they are also taking thiazide diuretics.
It has also been rarely reported to be due to other medicines. It can be very difficult to determine the exact cause of drug hypersensitivity syndrome if several medicines have been commenced in preceding weeks. In about 10% of cases, the causative drug is never identified.
Drug hypersensitivity syndrome is a delayed T cell-mediated reaction. Tissue damage is due to cytotoxic T cells and cytokine release.
Drug hypersensitivity syndrome usually develops over several days, with onset between 2 and 8 weeks after starting the responsible medicine.
A high fever of 38–40 C is usually noticed first. This is quickly followed by a widespread skin rash. Characteristics of the rash are diverse.
The rash can last many weeks.
Symptoms may worsen after stopping the drug and may continue for weeks or even months despite drug withdrawal. The severity of the rash does not necessarily correlate with the extent of internal organ involvement. Later symptoms depend on the internal organs affected. They may include:
The mortality from drug hypersensitivity syndrome is estimated at around 8%. Causes of death include:
The diagnosis of drug hypersensitivity syndrome is based on the clinical presentation of the triad of:
It is supported by eosinophilia and abnormal liver function tests.
As drug hypersensitivity syndrome can occur up to eight weeks after first exposure to the responsible drug, a great degree of care is required when determining the responsible medicine. A temporal association between medicine use and the start of the syndrome is the strongest evidence.
The European Registry of Severe Cutaneous Adverse Reactions to Drugs and Collection of Biological Samples (RegiSCAR) has produced diagnostic criteria to assist in the diagnosis of drug hypersensitivity syndrome. RegiSCAR inclusion criteria for potential cases require at least 3 of the following:
Attempts to confirm which drug has caused drug hypersensitivity syndrome may include patch tests. Patch testing has been reported to be most successful for antiepileptic drugs, with 50% positive reactions. It is not useful for allopurinol, with 0% positive reactions. Lymphocyte transformation testing is available in some centres, where specialist interpretation may reveal the causative drug in the majority of cases.
After taking a careful history and performing skin and general examination, the following tests may be requested.
Skin biopsy usually shows dense infiltration of inflammatory cells, including lymphocytes and eosinophils, extravasated erythrocytes, and oedema.
Blood tests may include:
Urinalysis is undertaken to assess renal damage.
A cardiac and pulmonary evaluation may include electrocardiograph (ECG), echocardiogram, and chest X-ray. Scans may be performed to evaluate liver, kidney and brain depending on symptoms and the results of initial tests.
Treatment consists of immediate withdrawal of all suspect medicines, followed by careful monitoring and supportive care. It is very important for patients presenting with a high fever and a rash, where a diagnosis of drug hypersensitivity syndrome is considered, to have blood tests as soon as possible.
Systemic steroids (eg, prednisone) are generally used in the more severe cases of drug hypersensitivity syndrome involving significant exfoliative dermatitis, pneumonitis and/or hepatitis. However, the benefits of corticosteroids are unknown as controlled clinical trials are lacking. Once effective, they should be withdrawn very slowly as the syndrome can recur as the dose reduces.
Supportive treatment for the skin rash may include:
Fluid, electrolytes and calorie intake may need attention. A warm environment and expert nursing care are required. Secondary infections may require antibiotics.
Patients who develop drug hypersensitivity syndrome must avoid taking the causative medicine/s again.
Cross-reactions are common between the three main aromatic anticonvulsant drugs (phenytoin, carbamazepine and phenobarbitone), and patients who have experienced drug hypersensitivity syndrome with any one of these medicines must avoid all three.
Because genetic factors are suspected in drug hypersensitivity syndrome, first-degree relatives should be alerted to their elevated risk of developing hypersensitivity reactions to the same medicine(s).
Most patients fully recover from drug hypersensitivity within weeks to months. Relapse after initial improvement is common.
Patients recovering from drug hypersensitivity syndrome are thought to be at risk of developing autoimmune diseases.
See the DermNet NZ bookstore.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.